6qba | pdb_00006qba

Crystal Structure of Retinol-Binding Protein 4 (RBP4) in complex with non-retinoid ligand A1120 and engineered binding scaffold

spinqualitylabelsall models 6qba, resolution 1.80Å Show:Asymmetric Unit Biological Assembly Drag the structure with the mouse to rotate   Export Animated Image   Print3D Structural highlights 6qba is a 2 chain structure with sequence from Atcc 35091 and Human. Full crystallographic information is available from OCA. For a guided tour on the structure components use FirstGlance. Ligands: 2T1, ACT, IMD, PEG, ZN Gene: RBP4, PRO2222 (HUMAN), sso7a1, sso7d-2, SSO9180, sso7a2, sso7d-3, SSO9535 (ATCC 35091) Resources: FirstGlance, OCA, PDBe, RCSB, PDBsum, ProSAT Disease [RET4_HUMAN] Defects in RBP4 are a cause of retinol-binding protein deficiency (RBP deficiency) [MIM:180250]. This condition causes night vision problems. It produces a typical 'fundus xerophthalmicus', featuring a progressed atrophy of the retinal pigment epithelium. Function [RET4_HUMAN] Delivers retinol from the liver stores to the peripheral tissues. In plasma, the RBP-retinol complex interacts with transthyretin, this prevents its loss by filtration through the kidney glomeruli. Publication Abstract from PubMed Molecular ON-switches in which a chemical compound induces protein-protein interactions can allow cellular function to be controlled with small molecules. ON-switches based on clinically applicable compounds and human proteins would greatly facilitate their therapeutic use. Here, we developed an ON-switch system in which the human retinol binding protein 4 (hRBP4) of the lipocalin family interacts with engineered hRBP4 binders in a small molecule-dependent manner. Two different protein scaffolds were engineered to bind to hRBP4 when loaded with the orally available small molecule A1120. The crystal structure of an assembled ON-switch shows that the engineered binder specifically recognizes the conformational changes induced by A1120 in two loop regions of hRBP4. We demonstrate that this conformation-specific ON-switch is highly dependent on the presence of A1120, as demonstrated by an approximately 500-fold increase in affinity upon addition of the small molecule drug. Furthermore, the ON-switch successfully regulated the activity of primary human CAR T cells in vitro. We anticipate that lipocalin-based ON-switches have the potential to be broadly applied for the safe pharmacological control of cellular therapeutics. A conformation-specific ON-switch for controlling CAR T cells with an orally available drug.,Zajc CU, Dobersberger M, Schaffner I, Mlynek G, Puhringer D, Salzer B, Djinovic-Carugo K, Steinberger P, De Sousa Linhares A, Yang NJ, Obinger C, Holter W, Traxlmayr MW, Lehner M Proc Natl Acad Sci U S A. 2020 Jun 30;117(26):14926-14935. doi:, 10.1073/pnas.1911154117. Epub 2020 Jun 17. PMID:32554495 From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See Also Retinol-binding protein 3D structures

Proteopedia Page Contributors and Editors (what is this?)

OCA